Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Feb 23, 2026

What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% and solid deleveraging capacity, Viatris combines deep-value characteristics with optionality from targeted acquisitions and shareholder returns. VTRS also anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands.

Seeking Alpha • Feb 20, 2026

Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 19, 2026

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.

GlobeNewsWire • Feb 19, 2026

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga • Feb 17, 2026

Dividend Income: Lanny's December 2025 Summary

In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, dividend increases created $4.44 in additional passive dividend income.

Seeking Alpha • Feb 17, 2026

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m.

PRNewsWire • Feb 3, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026.

PRNewsWire • Feb 3, 2026

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.

PRNewsWire • Jan 20, 2026